For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
58
references
 Top references
cited by
11
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      36
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Topical Review On Nano-vaccinology: Biochemical Promises and Key Challenges

      review-article
      Author(s): a , b , c , * , d
      Publication date (Electronic):
      Journal: Process Biochemistry (Barking, London, England)
      Publisher: Elsevier Ltd.
      Keywords: ISCOMS, Immune stimulating complexes, HIV, Human immune deficiency virus, HPV, Human papilloma virus, MRSA, Methcillin resistant Staphylococcus aureus, IgA, Immunoglobulin A, SARS-CoV-1, Severe acute respiratory syndrome Coronavirus-1, MERS, Middle-East respiratory syndrome, VLP, Virus like particles, SAPN, Self-Assembling Protein Nanoparticle, COVID-19, Corona virus disease-2019, PSNP, Polystyrene nanoparticles, PLGA, Poly(lactic-co-glycolic acid), CNT, Carbon nanotube, NMVs, Nano multilamellar lipid vesicles, CAPN, Calcium-phosphate nanoparticles, Chi-Alg, Chitosan alginate, Immunity, Nanoparticles, Vaccine, Pathogens, Prevention

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • •

            Nano-vaccines have promising potential to be materialized for personalized medical care

          • •

            Description of biological mechanisms for interaction making nano-vaccines successful

          • •

            Future insights for commercial up-scaling

          Abstract

          Nanomaterials have wide-ranging biomedical applications in prevention, treatment and control of diseases. Nanoparticle based vaccines have proven prodigious prophylaxis of various infectious and non-infectious diseases of human and animal concern. Nano-vaccines outnumber the conventional vaccines by virtue of plasticity in physio-chemical properties and ease of administration. The efficacy of nano-based vaccines may be attributed to the improved antigen stability, minimum immuno-toxicity, sustained release, enhanced immunogenicity and the flexibility of physical features of nanoparticles. Based on these, the nano-based vaccines have potential to evoke both cellular and humoral immune responses. Targeted and highly specific immunological pathways required for solid and long lasting immunity may be achieved with specially engineered nano-vaccines. This review presents an insight into the prevention of infectious diseases (of bacterial, viral and parasitic origin) and non-infectious diseases (cancer, auto-immune diseases) using nano-vaccinology. Additionally, key challenges to the effective utilization of nano-vaccines from bench to clinical settings have been highlighted as research domains for future.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: not found
          • Article: not found

          The COVID-19 vaccine development landscape

          Tung Thanh Le, Zacharias Andreadakis, Arun Kumar … (2020)
          Article 0 comments Cited 790 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Developing Covid-19 Vaccines at Pandemic Speed

            Nicole Lurie, Melanie Saville, Richard Hatchett … (2020)
            Article 0 comments Cited 703 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 Vaccines: Status Report

              Fatima Amanat, Florian Krammer (2020)
              SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
              Article 0 comments Cited 603 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Process Biochem
                Title: Process Biochemistry (Barking, London, England)
                Publisher: Elsevier Ltd.
                ISSN (Print): 1359-5113
                ISSN (Electronic): 1873-3298
                Publication date PMC-release: 28 September 2020
                Publication date (Electronic): 28 September 2020
                Affiliations
                [a ]Department of Parasitology, University of Agriculture, Faisalabad, Faisalabad 38040, Pakistan
                [b ]Federal University of Rio de Janeiro, Cidade Universitária, Rio de Janeiro - RJ, 21941-901, Brazil
                [c ]Wuhan University, 8 East Lake South Road, Wuchang 430072, Hubei Province,China
                [d ]Department of Pathology, University of Agriculture, Faisalabad, Faisalabad 38040, Pakistan
                Author notes
                [* ]Corresponding author at: Federal University of Rio de Janeiro, Cidade Universitária, Rio de Janeiro - RJ, 21941-901, Brazil.
                Article
                Publisher Item ID: S1359-5113(20)31326-X
                DOI: 10.1016/j.procbio.2020.09.028
                PMC ID: 7521878
                PubMed ID: 33013180
                SO-VID: 3d0a7599-a7b8-4ec5-87b4-0ef0876abe61
                Copyright © © 2020 Elsevier Ltd. All rights reserved.
                License:

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Date received : 19 August 2020
                Date revision received : 16 September 2020
                Date accepted : 23 September 2020
                Categories
                Subject: Article

                Keywords: iscoms, immune stimulating complexes,hiv, human immune deficiency virus,hpv, human papilloma virus,mrsa, methcillin resistant staphylococcus aureus,iga, immunoglobulin a,sars-cov-1, severe acute respiratory syndrome coronavirus-1,mers, middle-east respiratory syndrome,vlp, virus like particles,sapn, self-assembling protein nanoparticle,covid-19, corona virus disease-2019,psnp, polystyrene nanoparticles,plga, poly(lactic-co-glycolic acid),cnt, carbon nanotube,nmvs, nano multilamellar lipid vesicles,capn, calcium-phosphate nanoparticles,chi-alg, chitosan alginate,immunity,nanoparticles,vaccine,pathogens,prevention
                Data availability:
                Keywords: iscoms, immune stimulating complexes, hiv, human immune deficiency virus, hpv, human papilloma virus, mrsa, methcillin resistant staphylococcus aureus, iga, immunoglobulin a, sars-cov-1, severe acute respiratory syndrome coronavirus-1, mers, middle-east respiratory syndrome, vlp, virus like particles, sapn, self-assembling protein nanoparticle, covid-19, corona virus disease-2019, psnp, polystyrene nanoparticles, plga, poly(lactic-co-glycolic acid), cnt, carbon nanotube, nmvs, nano multilamellar lipid vesicles, capn, calcium-phosphate nanoparticles, chi-alg, chitosan alginate, immunity, nanoparticles, vaccine, pathogens, prevention

                Comments

                Comment on this article

                scite_

                Similar content36

                See all similar

                Cited by10

                See all cited by

                Most referenced authors838

                See all reference authors